PMID- 36730505
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230206
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 48
IP  - 2
DP  - 2023 Feb 2
TI  - A large case series on the use of diphencyprone immunotherapy in the clearance of 
      palmoplantar warts.
PG  - 96-99
LID - 10.1093/ced/llac046 [doi]
AB  - BACKGROUND: Palmoplantar viral warts are common, often affecting the quality of 
      life of patients and present a major therapeutic challenge. Immunotherapy using 
      diphencyprone (DCP) can be beneficial especially if first-line treatments fail. 
      AIM: To determine the effectiveness of DCP in clearing viral warts, and to 
      provide detail on the number of treatments required and any adverse effects 
      (AEs). METHODS: This was a retrospective case series of 124 patients who had 
      received DCP treatment in a UK private practice setting from 1991 to 2008, 
      carried out by a dermatologist experienced in the procedure. All patients had 
      been referred by other clinicians after failure of standard treatments. The study 
      data were extracted from clinical records, with follow-up until wart clearance or 
      treatment discontinuation. RESULTS: There was an equal distribution in sexes (63 
      females, 61 males), with 37% of patients having warts present for greater than 5 
      years. The majority (93%) of patients had already tried cryotherapy, which was 
      unsuccessful in clearing warts completely in all cases. Following DCP treatment, 
      77% of patients achieved full eradication of their warts, including three 
      patients who were immunosuppressed. The mean number of DCP treatments required to 
      achieve full clearance was 4.7, and the mean concentration of DCP required was 
      4%. Only 12% of patients experienced AEs, which were mild, and included urticaria 
      and blistering. CONCLUSION: We suggest that DCP immunotherapy is a safe and 
      effective treatment for eradicating viral warts, especially in recalcitrant 
      cases.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of British 
      Association of Dermatologists. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Chadha, Mehak
AU  - Chadha M
AD  - Department of Dermatology, King's College Hospital, London, UK.
FAU - Walsh, Sarah
AU  - Walsh S
AD  - Department of Dermatology, King's College Hospital, London, UK.
FAU - du Vivier, Anthony
AU  - du Vivier A
AD  - Department of Dermatology, King's College Hospital, London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - I7G14NW5EC (diphenylcyclopropenone)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Retrospective Studies
MH  - *Quality of Life
MH  - *Warts/drug therapy
MH  - Treatment Outcome
MH  - Immunotherapy
COIS- Conflict of interest The authors declare that they have no conflict of interest.
EDAT- 2023/02/03 06:00
MHDA- 2023/02/07 06:00
CRDT- 2023/02/02 14:14
PHST- 2022/08/20 00:00 [received]
PHST- 2022/10/17 00:00 [revised]
PHST- 2022/10/25 00:00 [accepted]
PHST- 2023/02/02 14:14 [entrez]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
AID - 6775964 [pii]
AID - 10.1093/ced/llac046 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2023 Feb 2;48(2):96-99. doi: 10.1093/ced/llac046.